Risk of pediatric AD is associated with childhood obesity and correlated to weight loss and gain.

Cendakimab is safe and efficacious in treating moderate-to-severe AD in adult patients.

AD patients have an increased risk of impaired mobility if they are male or aged 40 to 59 years.

High sodium intake is linked to an increased risk of AD and AD severity

Daily crisaborole ointment was efficacious in treating mild-to-moderate AD long-term

Topical treatment decreases itch and improves sleep patterns in patients with psoriasis and atopic dermatitis.

The visibility of a skin disorder is directly linked to stigma including bullying.

Early-life antibiotic use affects the gut microbiome which may lead to an increase risk of AD.